Aktienanalyse zu Kyntra Bio Inc (KYNB)KYNBKyntra Bio Inc

Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. It operates in the Healthcare sector.

Kyntra Bio Inc is a good buy right now due to its recent turnaround in net income, reporting $12 million in Q2 2026, which translates to $2.96 per share, a significant improvement from a net loss of $13.7 million in the same period last year. Additionally, the stock has shown a strong 5-day change of +6.65%, indicating positive momentum. However, investors should be cautious of the high operating costs, which reached $16.1 million in Q2 2026, as this could pressure profitability moving forward.